LAF-389

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameLAF-389
Drug Alias NameLAF-389NVP-LAF-389
ClassificationNatural product/ExtractSmall molecules
Mechanisms of ActionMethionine aminopeptidase 2 inhibitorsMethionine aminopeptidase 1 inhibitors
TargetsMethionine aminopeptidase 2Methionine aminopeptidase 1
Therapy Area/IndicationsMultiple MyelomaLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A